New shot targets lymphoma without chemo
NCT ID NCT07191249
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with a slow-growing type of lymphoma that hasn't been treated yet. The drug works by helping the body's immune cells find and kill cancer cells. About 30 adults will receive up to 8 cycles of treatment over roughly 6 months, and researchers will track how well the cancer responds and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mosunetuzumab (a drug that helps immune cells attack cancer cells)
What this could lead to
If successful, this could offer a less intensive first-line treatment option for people with a slow-growing form of lymphoma, potentially delaying the need for stronger therapies.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects like infusion reactions or infections, and it's not yet known if it works better than current approaches.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••